-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11

Benzinga·04/28/2025 11:16:42
Listen to the news
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $9 to $11.